The effect of topiramate plasma concentration on linguistic behavior, verbal recall and working memory

Epilepsy and Behavior

Volumn 24, Issue 3, 2012, Pages 365-372

  Marino, S E ^a   Pakhomov, S V S ^a   Han, S ^b   Anderson, K L ^b   Ding, M ^b   Eberly, L E ^c   Loring, D W ^d   Hawkins Taylor, C ^a   Rarick, J O ^a   Leppik, I E ^a   Cibula, J E ^e   Birnbaum, A K ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b University of Florida   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

Author keywords

Cognition; Plasma concentration; Reaction time; Spontaneous speech; Topiramate; Verbal fluency

Indexed keywords

DRUG DERIVATIVE; FRUCTOSE; TOPIRAMATE;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; LEARNING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; RECALL; SHORT TERM MEMORY; SPEECH;

ADOLESCENT; ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FRUCTOSE; HUMANS; MALE; MEMORY, SHORT-TERM; MENTAL RECALL; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; REACTION TIME; SPEECH; VERBAL LEARNING;

EID: 85027944792     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2012.04.120     Document Type: Article

References (49)

1. Aldenkamp, A.P., De Krom, M., Reijs, R., Newer antiepileptic drugs and cognitive issues. Epilepsia 44:Suppl. 4 (2003), 21–29.
2. Lee, H.W., Jung, D.K., Suh, C.K., Kwon, S.H., Park, S.P., Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: a 1-year follow-up. Epilepsy Behav 8:4 (2006), 736–741.
3. Thompson, P.J., Baxendale, S.A., Duncan, J.S., Sander, J.W., Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 69:5 (2000), 636–641.
4. Mula, M., Trimble, M.R., Thompson, P., Sander, J.W., Topiramate and word-finding difficulties in patients with epilepsy. Neurology 60:7 (2003), 1104–1107.
5. Dodgson, S.J., Shank, R.P., Maryanoff, B.E., Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 41:Suppl. 1 (2000), S35–S39.
6. Shank, R.P., Maryanoff, B.E., Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neurosci Ther 14:2 (2008), 120–142.
7. Coppola, F., Rossi, C., Mancini, M.L., et al. Language disturbances as a side effect of prophylactic treatment of migraine. Headache 48:1 (2008), 86–94.
8. Bootsma, H.P., Coolen, F., Aldenkamp, A.P., et al. Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 5:3 (2004), 380–387.
9. Tatum, W.O.t, French, J.A., Faught, E., et al. Postmarketing experience with topiramate and cognition. Epilepsia 42:9 (2001), 1134–1140.
10. Meador, K.J., Cognitive outcomes and predictive factors in epilepsy. Neurology 58:8 Suppl. 5 (2002), S21–S26.
11. Loring, D.W., Williamson, D.J., Meador, K.J., Wiegand, F., Hulihan, J., Topiramate dose effects on cognition: a randomized double-blind study. Neurology 76:2 (2011), 131–137.
12. Kockelmann, E., Elger, C.E., Helmstaedter, C., Significant improvement in frontal lobe associated neuropsychological functions after withdrawal of topiramate in epilepsy patients. Epilepsy Res 54:2–3 (2003), 171–178.
13. Martin, R., Kuzniecky, R., Ho, S., et al. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology 52:2 (1999), 321–327.
14. Ojemann, L.M., Ojemann, G.A., Dodrill, C.B., Crawford, C.A., Holmes, M.D., Dudley, D.L., Language disturbances as side effects of topiramate and zonisamide therapy. Epilepsy Behav 2:6 (2001), 579–584.
15. Meador, K.J., Loring, D.W., Hulihan, J.F., Kamin, M., Karim, R., Differential cognitive and behavioral effects of topiramate and valproate. Neurology 60:9 (2003), 1483–1488.
16. Kockelmann, E., Elger, C.E., Helmstaedter, C., Cognitive profile of topiramate as compared with lamotrigine in epilepsy patients on antiepileptic drug polytherapy: relationships to blood serum levels and comedication. Epilepsy Behav 5:5 (2004), 716–721.
17. Blum, D., Meador, K., Biton, V., et al. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology 67:3 (2006), 400–406.
18. Salinsky, M.C., Storzbach, D., Spencer, D.C., Oken, B.S., Landry, T., Dodrill, C.B., Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers. Neurology 64:5 (2005), 792–798.
19. Romigi, A., Cervellino, A., Marciani, M.G., et al. Cognitive and psychiatric effects of topiramate monotherapy in migraine treatment: an open study. Eur J Neurol 15:2 (2008), 190–195.
20. Fritz, N., Glogau, S., Hoffmann, J., Rademacher, M., Elger, C.E., Helmstaedter, C., Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 6:3 (2005), 373–381.
21. Froscher, W., Schier, K.R., Hoffmann, M., et al. Topiramate: a prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy. Epileptic Disord 7:3 (2005), 237–248.
22. De Ciantis, A., Muti, M., Piccolini, C., et al. A functional MRI study of language disturbances in subjects with migraine headache during treatment with topiramate. Neurol Sci 29:Suppl. 1 (2008), S141–S143.
23. Ravizza, S.M., McCormick, C.A., Schlerf, J.E., Justus, T., Ivry, R.B., Fiez, J.A., Cerebellar damage produces selective deficits in verbal working memory. Brain 129:Pt. 2 (2006), 306–320.
24. Schweizer, T.A., Alexander, M.P., Susan Gillingham, B.A., Cusimano, M., Stuss, D.T., Lateralized cerebellar contributions to word generation: a phonemic and semantic fluency study. Behav Neurol 23:1–2 (2010), 31–37.
25. Chaytor, N., Schmitter-Edgecombe, M., Burr, R., Improving the ecological validity of executive functioning assessment. Arch Clin Neuropsychol 21:3 (2006), 217–227.
26. Heller, R.B., Dobbs, A.R., Age differences in word finding in discourse and nondiscourse situations. Psychol Aging 8:3 (1993), 443–450.
27. Rohrer, J.D., Knight, W.D., Warren, J.E., Fox, N.C., Rossor, M.N., Warren, J.D., Word-finding difficulty: a clinical analysis of the progressive aphasias. Brain 131:Pt. 1 (2008), 8–38.
28. Shriberg, E., Higher level features in speaker recognition. Muller, C., (eds.) Speaker classification I of lecture notes in computer science/artificial intelligence, 2007, Springer, Heidelberg/Berlin/New York, 241–259.
29. Shriberg, E., Ferrer, L., Kajarekar, S., Venkataraman, A., Stolcke, A., Modeling prosodic feature sequences for speaker recognition. Speech Commun 46:3–4 (2005), 455–472.
30. Shriberg, E., Stolcke, A., (eds.) The case for automatic higher-level features in forensic speaker recognition Interspeech, 2008 Brisbane, Australia.
31. Roark, B., Hosom, J., Mitchell, M., Kaye, J.A., Automatically derived spoken language markers for detecting mild cognitive impairment. International Conference on Technology and Aging (ICTA), 2007.
32. Hosom, J.P., Shriberg, L., Green, J.R., Diagnostic assessment of childhood apraxia of speech using automatic speech recognition (ASR) methods. J Med Speech Lang Pathol 12:4 (2004), 167–171.
33. Pakhomov, S.V., Smith, G.E., Chacon, D., et al. Computerized analysis of speech and language to identify psycholinguistic correlates of frontotemporal lobar degeneration. Cogn Behav Neurol 23:3 (2010), 165–177.
34. Sternberg, S., Memory-scanning: mental processes revealed by reaction-time experiments. Am Sci 57:4 (1969), 421–457.
35. Motamedi, G., Meador, K., Epilepsy and cognition. Epilepsy Behav 4:Suppl. 2 (2003), S25–S38.
36. Lezak, M.D., Howieson, D.B., Loring, D.W., (eds.) Neuropsychological assessment, 4th edition, 2004, Oxford University Press.
37. Benton, A.L., Hamsher, K., Sivan, A.B., Multilingual aphasia examination. 3rd edition, 1983, AJA Associates, Iowa City.
38. Meador, K.J., Loring, D.W., Abney, O.L., et al. Effects of carbamazepine and phenytoin on EEG and memory in healthy adults. Epilepsia 34:1 (1993), 153–157.
39. Pakhomov, S.V., Smith, G.E., Marino, S., et al. A computerized technique to assess language use patterns in patients with frontotemporal dementia. J Neurolinguist 23:2 (2010), 127–144.
40. Nicholas, L.E., Brookshire, R.H., A system for quantifying the informativeness and efficiency of the connected speech of adults with aphasia. J Speech Hear Res 36:2 (1993), 338–350.
41. Yorkston, K.M., Beukelman, D.R., An analysis of connected speech samples of aphasic and normal speakers. J Speech Hear Disord 45:1 (1980), 27–36.
42. Zhu, H., Luo, J., A fast and sensitive liquid chromatographic–tandem mass spectrometric method for assay of lorazepam and application to pharmacokinetic analysis. J Pharm Biomed Anal 39:1–2 (2005), 268–274.
43. FDA, Guidance for industry: bioanalytical method validation. In: Services USDoHaH, editor. Rockville, MD. 2001.
44. Salinsky, M., Storzbach, D., Oken, B., Spencer, D., Topiramate effects on the EEG and alertness in healthy volunteers: a different profile of antiepileptic drug neurotoxicity. Epilepsy Behav 10:3 (2007), 463–469.
45. Bourgeois, B.F., Pharmacokinetics and metabolism of topiramate. Drugs Today (Barc) 35:1 (1999), 43–48.
46. Cirulli, E.T., Urban, T.J., Marino, S.E., et al. Genetic and environmental correlates of topiramate-induced cognitive impairment. Epilepsia 53:1 (2012), e5–e8.
47. Christensen, J., Hojskov, C.S., Dam, M., Poulsen, J.H., Plasma concentration of topiramate correlates with cerebrospinal fluid concentration. Ther Drug Monit 23:5 (2001), 529–535.
48. Reife, R.A., Topiramate. Shorvon, S., Dreifuss, F., Fish, D., Thomas, D., (eds.) The treatment of epilepsy, 1996, Blackwell Science Ltd., Oxford, 471–481.
49. Ross, T.P., Calhoun, E., Cox, T., Wenner, C., Kono, W., Pleasant, M., The reliability and validity of qualitative scores for the controlled oral word association test. Arch Clin Neuropsychol 22:4 (2007), 475–488.